Phase 1RecruitingPriority 4 · Lower priorityNCT04234048
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Plain-language summary
This Phase 1 trial is testing Fenretinide for people whose a type of T-cell lymphoma called AITL has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 10 US locations across multiple states.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Fenretinide (DRUG): Accelerated Phase 1a 100% Dose escalation in 8 single-patient cohorts Standard Phase 1a 40% Dose escalation in 3-patient cohorts X 3 cohorts Phase 1b Dosed at MTD in 20 patients as disease-specific expanded cohort
- Drugs / treatments
- Fenretinide
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details